Literature DB >> 18160777

Microdeletions in 9p21.3 induce false negative results in CDKN2A FISH analysis of Ewing sarcoma.

S Savola1, F Nardi, K Scotlandi, P Picci, S Knuutila.   

Abstract

Deletion of the CDKN2A locus at 9p21.3 has been reported to be a poor prognostic sign in the Ewing sarcoma family of tumours. In clinical applications CDKN2A deletion is primarily detected using fluorescent in situ hybridisation (FISH) with a commercial probe, size approximately 190 kb. Due to limitations in resolution, FISH analysis may fail to detect microdeletions smaller than 190 kb. In the present study, we performed 44K array comparative genomic hybridisation (CGH) on eleven Ewing sarcoma cell lines and 26 tissue samples in order to define the sizes of 9p21.3 deletions. Microarray CGH analysis revealed 9p21.3 deletions encompassing the CDKN2A locus in eight cell lines (73%) and in six tumours (23%). In four cases (two cell lines and two tissue samples) the deletion was less than 190 kb in size. In one cell line sample, we detected a microdeletion of approximately 58 kb in 9p21.3 harbouring the CDKN2A locus. We confirmed this result using 244K microarray CGH and TaqMan quantitative RT-PCR analysis and further performed FISH analysis on this cell line sample. Here, we show that CDKN2A FISH analysis can give false negative results in cases with small microdeletions. Our results suggest that new and more accurate FISH methods should be developed for detection of deletions in the CDKN2A locus. Copyright (c) 2007 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18160777     DOI: 10.1159/000109614

Source DB:  PubMed          Journal:  Cytogenet Genome Res        ISSN: 1424-8581            Impact factor:   1.636


  7 in total

Review 1.  Ewing sarcoma/peripheral primitive neuroectodermal tumor and related tumors.

Authors:  Maria Tsokos; Rita D Alaggio; Louis P Dehner; Paul S Dickman
Journal:  Pediatr Dev Pathol       Date:  2012

2.  High resolution array comparative genomic hybridization identifies copy number alterations in diffuse large B-cell lymphoma that predict response to immuno-chemotherapy.

Authors:  F Kreisel; S Kulkarni; R T Kerns; A Hassan; H Deshmukh; R Nagarajan; J L Frater; A Cashen
Journal:  Cancer Genet       Date:  2011-03

3.  Adult NTRK-rearranged spindle cell neoplasms of the viscera: with an emphasis on rare locations and heterologous elements.

Authors:  Jen-Wei Tsai; Jen-Chieh Lee; Tsung-Han Hsieh; Shih-Chiang Huang; Pei-Hang Lee; Ting-Ting Liu; Yu-Chien Kao; Ching-Di Chang; Te-Fu Weng; Chien-Feng Li; Jung-Chia Lin; Cher-Wei Liang; Yu-Li Su; Ian Yi-Feng Chang; Yu-Ting Wang; Nien-Yi Chang; Shih-Chen Yu; Jui-Chu Wang; Hsuan-Ying Huang
Journal:  Mod Pathol       Date:  2022-02-11       Impact factor: 8.209

4.  Copy Number Alterations and Methylation in Ewing's Sarcoma.

Authors:  Mona S Jahromi; Kevin B Jones; Joshua D Schiffman
Journal:  Sarcoma       Date:  2011-03-15

5.  Droplet digital polymerase chain reaction offers an improvisation over conventional immunohistochemistry and fluorescent in situ hybridization for ascertaining Her2 status of breast cancer.

Authors:  Moushumi Suryavanshi; Jiten Jaipuria; Anurag Mehta; Dushyant Kumar; Manoj Kumar Panigrahi; Haristuti Verma; Mumtaz Saifi; Sanjeev Sharma; Simran Tandon; Dinesh Chandra Doval; Bhudev C Das
Journal:  South Asian J Cancer       Date:  2019 Oct-Dec

6.  Combined use of expression and CGH arrays pinpoints novel candidate genes in Ewing sarcoma family of tumors.

Authors:  Suvi Savola; Arto Klami; Abhishek Tripathi; Tarja Niini; Massimo Serra; Piero Picci; Samuel Kaski; Diana Zambelli; Katia Scotlandi; Sakari Knuutila
Journal:  BMC Cancer       Date:  2009-01-14       Impact factor: 4.430

Review 7.  Challenges and future of biomarker tests in the era of precision oncology: Can we rely on immunohistochemistry (IHC) or fluorescence in situ hybridization (FISH) to select the optimal patients for matched therapy?

Authors:  Young Kwang Chae; Ayush Arya; Lauren Chiec; Hiral Shah; Ari Rosenberg; Sandip Patel; Kirtee Raparia; Jaehyuk Choi; Derek A Wainwright; Victoria Villaflor; Massimo Cristofanilli; Francis Giles
Journal:  Oncotarget       Date:  2017-08-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.